Literature DB >> 18091763

Advances in the treatment of breast cancer.

S Moulder1, G N Hortobagyi.   

Abstract

Breast cancer is the most commonly diagnosed cancer in American women and is the second leading cause of cancer-related deaths in this population. This review highlights how the use of a multidisciplinary approach to the management of diseases of the breast and the introduction of novel systemic therapies have improved the quality of life and survival in patients with breast cancer.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18091763     DOI： 10.1038/sj.clpt.6100449

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  32 in total

1.  Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.

Authors:  Shu Zhang; KyoungHyun Kim; Un Ho Jin; Catherine Pfent; Huojun Cao; Brad Amendt; Xinyi Liu; Heather Wilson-Robles; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2011-10-27       Impact factor: 6.261

2.  Monitoring the Effect of Docetaxel Treatment in MCF7 Xenografts Using Multimodal In Vivo and Ex Vivo Magnetic Resonance Methods, Histopathology, and Gene Expression.

Authors:  Else Marie Huuse; Line Rørstad Jensen; Pål Erik Goa; Steinar Lundgren; Endre Anderssen; Anna Bofin; Ingrid Susann Gribbestad; Tone Frost Bathen
Journal:  Transl Oncol       Date:  2010-08-01       Impact factor: 4.243

3.  Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer.

Authors:  Xinyi Liu; Indira Jutooru; Ping Lei; KyoungHyun Kim; Syng-Ook Lee; Lisa K Brents; Paul L Prather; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2012-05-02       Impact factor: 6.261

4.  Cluster of symptoms in women with breast cancer treated with curative intent.

Authors:  Alexandre Lopes Evangelista; Erika Maria Monteiro Santos
Journal:  Support Care Cancer       Date:  2011-08-16       Impact factor: 3.603

5.  The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy.

Authors:  Shu Zhang; Ping Lei; Xinyi Liu; Xiangrong Li; Kelcey Walker; Leela Kotha; Craig Rowlands; Stephen Safe
Journal:  Endocr Relat Cancer       Date:  2009-05-15       Impact factor: 5.678

6.  Breast cancer in the personal genomics era.

Authors:  Rachel E Ellsworth; David J Decewicz; Craig D Shriver; Darrell L Ellsworth
Journal:  Curr Genomics       Date:  2010-05       Impact factor: 2.236

7.  Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.

Authors:  Yu Shen; Wenli Dong; Barry W Feig; Peter Ravdin; Richard L Theriault; Sharon H Giordano
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

Review 8.  The costs of treating breast cancer in the US: a synthesis of published evidence.

Authors:  Jonathan D Campbell; Scott D Ramsey
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.

Authors:  Xinyi Liu; Maen Abdelrahim; Ala Abudayyeh; Ping Lei; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2009-05-12       Impact factor: 6.261

10.  Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.

Authors:  Anne-Sofie Schrohl; Maxime P Look; Marion E Meijer-van Gelder; John A Foekens; Nils Brünner
Journal:  BMC Cancer       Date:  2009-09-10       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.